|
業務類別
|
Biotechnology |
|
業務概覽
|
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. |
| 公司地址
| 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139 |
| 電話號碼
| +1 857 242-1600 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.sperotherapeutics.com |
| 員工數量
| 25 |
| Mr. Timothy Keutzer |
Chief Operating Officer |
美元 484.57K |
27/04/2026 |
| Ms. Esther Rajavelu |
Director, President, Chief Business Officer, Chief Executive Officer, Principal Accounting Officer, Chief Financial Officer and Treasurer |
美元 577.18K |
27/04/2026 |
|
|
| Mr. Scott T. Jackson, M.B.A. |
Independent Director |
27/04/2026 |
| Ms. Kathleen Tregoning, M.A. |
Independent Director |
27/04/2026 |
| Ms. Esther Rajavelu |
Director, President, Chief Business Officer, Chief Executive Officer, Principal Accounting Officer, Chief Financial Officer and Treasurer |
27/04/2026 |
| Dr. Patrick V.J.J. Vink, M.D. |
Independent Director |
27/04/2026 |
| Ms. Cynthia Smith |
Independent Director |
27/04/2026 |
| Dr. Milind S. Deshpande, PhD |
Independent Director |
27/04/2026 |
| Dr. John C. Pottage,Jr,M.D. |
Director |
27/04/2026 |
| Mr. Frank E. Thomas |
Chairman of the Board |
27/04/2026 |
|
|
|
|
